68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer (NCT07508852) | Clinical Trial Compass
RecruitingPhase 1/2
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
China30 participantsStarted 2025-10-22
Plain-language summary
This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adults.
* Histologically confirmed small cell lung cancer (SCLC).
* At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.
* Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.
Exclusion Criteria:
* Pregnancy.
* Breastfeeding.
* Acute psychiatric disorders.
* Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).
* Inability to complete the study procedures as anticipated.
* Prior therapy targeting DLL3.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial uses a new imaging agent called 68Ga-PFD3 that targets something called DLL3 — can you explain what DLL3 is and whether my tumor has been tested for it, since the trial seems to be specifically looking at how the imaging relates to DLL3 levels?
2Since this is a Phase 1/2 trial, the safety profile of this imaging agent isn't fully established yet — what do the CTCAE adverse event grades they're tracking tell us about what side effects have been seen so far, and how does that affect whether this is right for me?
3I have either limited-stage or extensive-stage SCLC — does my specific stage affect how useful this PFD3 PET scan might be for understanding my disease, and is one group expected to benefit more from this kind of imaging?
4If I take part in this trial and get the PFD3 PET scan, how would the results actually influence my treatment plan, or is this purely a diagnostic research study that wouldn't change what therapy I receive?
5Are there standard imaging options like conventional PET or CT scans that my care team would normally use for my SCLC, and how would participating in this trial compare to or interact with those standard diagnostic approaches?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Adverse events (assessed using CTCAE grades)
Timeframe: 1 week after injection
2
Correlation between PFD3 uptake and DLL3 expression